Hengsai Bio

Shanghai, China · Founded 2018 · Privately Held (backing)

Developer of personalized dendritic cell tumor vaccines intended to provide new treatment approaches and strategies for relapsed and refractory tumors. Hengsai Bio is based in Shanghai, China and was founded in 2018. It has raised $18.6 million.

Last price · $/share
—
Implied valuation
—
Total raised
$18.6M
Last round
—
Valuation — not yet established

No valuation for Hengsai Bio is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($18.6M) and the funding record below are the closest available signals.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Hengsai Bio with a free account
  • ·Watch Hengsai Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Hengsai Bio funding history

No rounds on record

No funding rounds for Hengsai Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

How Hengsai Bio's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Hengsai Bio, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about Hengsai Bio

How much has Hengsai Bio raised?
Hengsai Bio has raised $18.6M in total funding across its recorded rounds.